Comparison of three commercially available ELISA assays for anti-infliximab antibodies

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 873 citations

Medicine, Pharmacokinetics, Pharmacology +16

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Nicholas A. Kennedy, Graham Heap, Harry Green et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 677 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif, Edward V. Loftus, William A. Faubion et al. · The American Journal of Gastroenterology · 2010 · 487 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 454 citations

Medicine, Clinical Sciences, Pharmacotherapy +17

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

Niels Vande Casteele, Ann Gils, Sharat Singh et al. · The American Journal of Gastroenterology · 2013 · 344 citations

Pharmacy, Pharmacokinetics, Pharmacology +17